Evidence map›Paper›PMID 41966692›Full record

ArticleCell reports. Medicine2026

Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small-cell lung cancer.

Zhuo Wang, Qing Luo, Jie Wu, Li Lu, Wenjie Ding, Yichun Zhao, Yongfeng Yu, Ruoran Qiu, Ling Zhu, Xinxing Ouyang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Zhuo WangShanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China.
Qing LuoDepartment of Physiology and Pharmacology, Karolinska Institutet, 17177 Stockholm, Sweden.
Jie WuDepartment of Pathology, Shanghai Jiahui International Hospital, Shanghai 200233, China.
Li LuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Wenjie DingDepartment of Pathology, Shanghai Jiahui International Hospital, Shanghai 200233, China.
Yichun ZhaoShanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China.
Yongfeng YuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Ruoran QiuShanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China.
Ling ZhuShanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China.
Xinxing OuyangShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Wendi XuzhangShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
Shun LuShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. Electronic address: shunlu@sjtu.edu.cn.
Wei WeiInstitute for Systems Biology, Seattle, WA 98109, USA. Electronic address: wwei@systemsbiology.org.
Qihui ShiShanghai Key Laboratory of Clinical Geriatric Medicine, Huadong Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai 200040, China; Minhang Hospital, Fudan University, Shanghai 201100, China; Shanghai Engineering Research Center of Biomedical Analysis Reagents, Fudan Zhang Jiang Institute, Shanghai 201203, China. Electronic address: qihuishi@fudan.edu.cn.
Ziming LiShanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. Electronic address: liziming1980@shsmu.edu.cn.

Funding

Spatiotemporal Tumor Analytics for Guiding Sequential Targeted-Inhibitor: Immunotherapy Combinations (ST-Analytics)U54CA274509 · NCI · INSTITUTE FOR SYSTEMS BIOLOGY · PI Rong Fan · 2022 to 2026
$15.6M
NCI NIH HHS U54 CA274509
6 · The paper itself

Abstract

Combined small-cell lung cancer (cSCLC) is an aggressive subtype of SCLC with mixed histologic components. Despite heterogeneity and poorer prognosis than de novo SCLC, cSCLC is managed as SCLC because molecular insight into biology, lineage plasticity, and tumor microenvironment (TME) is limited. We perform spatial whole-exome sequencing, spatial transcriptomics, and single-nucleus RNA sequencing across 19 treatment-naive cSCLC tumors. Different histologic components share a monoclonal origin, whereas divergence associates with distinct mutation and copy-number alteration patterns. Our results define spatially exclusive or interspersed tumor domains with distinct TME and immune landscapes; fibroblast-rich boundaries enriched for an aggressive fibroblast subtype may shape TME and treatment responses. We identify lineage plasticity, including adenocarcinoma-to-SCLC transdifferentiation and SCLC-subtype coexistence, and develop cSCLC Detector, a sensitive mutation-based assay improving cSCLC detection in tissue and liquid biopsies. These findings illuminate cSCLC evolution and heterogeneity, underscoring the need for tailored diagnostic and therapeutic strategies for this aggressive subtype.

Indexed as

Lung NeoplasmsSmall Cell Lung CarcinomaTumor MicroenvironmentCell PlasticityExome SequencingFemaleHumansMultiomicsMutationSpatial Transcriptomicscombined small-cell lung cancercSCLCLUAD-to-SCLC transdifferentiationsingle-nucleus RNA sequencingsnRNA-seqspatially resolved whole-exome sequencingspatial transcriptomicsSTTMEtumor microenvironmentWES

Identifiers

PMID41966692
PMCPMC13130634

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.